Halozyme Therapeutics, Inc. (NASDAQ:HALO)

CAPS Rating: 2 out of 5

A biopharmaceutical company dedicated to the development and commercialization of recombinant human enzymes for the drug delivery, palliative care, oncology and infertility markets.

Recs

0
Player Avatar old3puttdean (34.72) Submitted: 5/2/2007 11:46:53 PM : Outperform Start Price: $10.25 HALO Score: -12.05

The potential from a $600 Million deal with Roche sounds good to me.

Featured Broker Partners


Advertisement